|
Right Treatment, Right Patient: Evidence-Based Approaches to the Treatment of Moderate-to-Severe Atopic Dermatitis Snippet 1: Currently Available Injectable Biologic Therapies for Moderate-to-Severe Atopic Dermatitis (AD)
Target Audience
This activity is designed to meet the educational needs of dermatology and allergy physicians, nurse practitioners, PAs, and nurses who care for patients with moderate-to-severe atopic dermatitis.
Program Overview
This activity features a case presentation, a brief overview of currently available injectable biologic therapies, and insights from an expert faculty.
Learning Objectives
After completing this activity, the participant should be better able to::
Identify ... |
|
Diabetes Update 2024 - LIVE STREAMING
This highly rated Harvard Medical School CME course offers practical strategies to address the medical and systemic challenges to optimal care and updates that ensure you can deliver state-of-the-art care for your patients with diabetes.
PROGRAM HIGHLIGHTS
This program affords you the opportunity to learn from leaders in the field of diabetes who are distinguished for their outstanding teaching, knowledge, and innovations in clinical care.
Participants can rely on this program for compreh... |
|
Gastroenterology 2024 - LIVE STREAMING
The Comprehensive 2024 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2024 program include:
• Updated... |
|
Right Treatment, Right Patient: Evidence-Based Approaches to the Treatment of Moderate-to-Severe Atopic Dermatitis Snippet 2: Currently Available Oral Therapies for Moderate-to-Severe Atopic Dermatiti
Target Audience
This activity is designed to meet the educational needs of dermatology and allergy physicians, nurse practitioners, PAs, and nurses who care for patients with moderate-to-severe atopic dermatitis.
Program Overview
This activity features a case presentation, a brief overview of currently available oral therapies, and insights from expert faculty.
Learning Objectives
After completing this activity, the participant should be better able to::
Identify the biologic prope... |
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |